Novo Nordisk A/S (NVO): Price and Financial Metrics

Novo Nordisk A/S (NVO): $92.60

1.23 (+1.35%)

POWR Rating

Component Grades














  • NVO scores best on the Quality dimension, with a Quality rank ahead of 99.08% of US stocks.
  • NVO's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
  • NVO's current lowest rank is in the Momentum metric (where it is better than 5.04% of US stocks).

NVO Stock Summary

  • With a market capitalization of $215,001,500,000, Novo Nordisk A S has a greater market value than 99.12% of US stocks.
  • NVO's went public 35.6 years ago, making it older than 92.76% of listed US stocks we're tracking.
  • With a year-over-year growth in debt of 161.44%, Novo Nordisk A S's debt growth rate surpasses 93.67% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Novo Nordisk A S are NVS, ABT, TMO, PEP, and MRK.
  • NVO's SEC filings can be seen here. And to visit Novo Nordisk A S's official web site, go to

NVO Stock Price Chart Interactive Chart >

Price chart for NVO

NVO Price/Volume Stats

Current price $92.60 52-week high $92.87
Prev. close $91.37 52-week low $63.22
Day low $92.29 Volume 724,300
Day high $92.87 Avg. volume 952,744
50-day MA $84.51 Dividend yield 1.44%
200-day MA $74.33 Market Cap 218.05B

Novo Nordisk A/S (NVO) Company Bio

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. The company was founded in 1925 and is based in Bagsvaerd, Denmark.

NVO Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$92.60$179.95 121%

We started the process of determining a valid price forecast for Novo Nordisk A S with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Novo Nordisk A S ranked in the 72th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 122.5%. The most interesting components of our discounted cash flow analysis for Novo Nordisk A S ended up being:

  • As a business, NVO is generating more cash flow than 99.1% of positive cash flow stocks in the Healthcare.
  • The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately just 6.54% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • NVO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 57.22% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as NVO, try PKI, HRC, ABBV, VASO, and SUPN.

NVO Latest News Stream

Event/Time News Detail
Loading, please wait...

NVO Latest Social Stream

Loading social stream, please wait...

View Full NVO Social Stream

Latest NVO News From Around the Web

Below are the latest news stories about Novo Nordisk A S that investors may wish to consider to help them evaluate NVO as an investment opportunity.

Let the games begin- Novo Nordisk takes the gold in Cowens R&D pentathlon Endpoints News

Let the games begin: Novo Nordisk takes the gold in Cowen''s ''R&D pentathlon'' Endpoints News

Endpoints News | July 30, 2021

15 Most Valuable Biotech Companies in the World

In this article we will take a look at the 15 most valuable biotech companies in the world. You can skip our detailed analysis of the biotechnology industry’s outlook for 2021, and some of the major growth catalysts for biotech stocks, and go directly to the 5 Most Valuable Biotech Companies in the World. Mankind […]

Yahoo | July 30, 2021

Global Glucagon Drug Market (2021-2026) | Latest COVID19 Impact Analysis | Know About Brand Players - Novo Nordisk, Eli Lilly, Fresenius Kabi, Torrent Labs

The recent report titled Global Glucagon Drug Market and forecast to 2026 published by Reportsweb is a focused study encompassing the market segmentation primarily based on type and application. The report investigates the key drivers leading to the growth of

OpenPR | July 28, 2021

Diabetes Monitoring Devices Market to Witness Huge Growth by Key Players: Dexcom, B. Braun Melsungen AG, Medtronic, Abbott Laboratories, LifeScan, ARKRAY, Novo Nordisk

According to Market Study Report, Diabetes Monitoring Devices Market provides a comprehensive analysis of the Diabetes Monitoring Devices Market segments, including their dynamics, size, growth, regulatory requirements, competitive landscape, and emerging opportunities of global industry. Get Free Sample Copy of Diabetes

OpenPR | July 28, 2021

10 Most Valuable Companies in Europe

In this article we will take a look at the 10 most valuable companies in Europe. However, you can skip our detailed analysis of these European companies, and go directly to the 5 Most Valuable Companies in Europe. Although Europe is the second smallest continent in the world, it has one of the largest economies […]

Yahoo | July 26, 2021

Read More 'NVO' Stories Here

NVO Price Returns

1-mo 9.19%
3-mo 22.91%
6-mo 31.77%
1-year 43.94%
3-year 95.64%
5-year 80.88%
YTD 33.89%
2020 22.56%
2019 27.79%
2018 -12.54%
2017 52.92%
2016 -37.03%

NVO Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full NVO Dividend History

Continue Researching NVO

Want to see what other sources are saying about Novo Nordisk A S's financials and stock price? Try the links below:

Novo Nordisk A S (NVO) Stock Price | Nasdaq
Novo Nordisk A S (NVO) Stock Quote, History and News - Yahoo Finance
Novo Nordisk A S (NVO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9449 seconds.